Get the Daily Brief
Latest Biotech News
NeoGenomics Revises Guidance After Q2 Revenue Growth Slows
NeoGenomics reported a 10% revenue increase for the second quarter driven by clinical testing growth but slashed full-year revenue and earnings forecasts following delays and challenges in...
Advances in Gene Set Analysis via AI-Verified Model
The NIH unveiled GeneAgent, an artificial intelligence system that mitigates hallucination errors in gene function prediction by autonomously cross-verifying outputs against curated biological...
GeneDx Posts 49% Q2 Revenue Surge Fueled by Genome Testing
GeneDx reported a 49% increase in second-quarter revenues to $102.7 million, surpassing Wall Street estimates and marking its fourth consecutive profitable quarter. The growth was primarily driven...
Sarepta Resumes Duchenne Gene Therapy Shipments After FDA Reversal
Sarepta Therapeutics has recommenced shipments of its gene therapy Elevidys® to ambulatory patients with Duchenne muscular dystrophy following a brief FDA-mandated pause. The reversal comes after...
Merck Launches $3 Billion Annual Cost-Cutting Plan by 2027
Merck announced an extensive cost reduction program aimed at saving $3 billion annually by 2027 to offset declining sales of Gardasil and upcoming patent expiration of Keytruda. The multiyear...
Labcorp Secures CE-IVDR Mark for Pan-Solid Tumor Profiling Test
Labcorp announced it received CE-IVDR marking from European regulators for its PGDx Elio Tissue Complete assay, a next-generation sequencing test for pan-solid tumor profiling. This regulatory...
Artbio Raises $132 Million Series B To Advance Radiopharmaceuticals
European radiopharmaceutical startup Artbio secured a $132 million Series B financing to propel its lead prostate cancer alpha radioligand therapeutic into early clinical testing. The funding will...
Celcuity Breast Cancer Combo Hits Phase 3 Endpoints, Shares Surge
Celcuity announced positive top-line results from a Phase 3 trial evaluating its experimental breast cancer drug gedatolisib in combination with standard therapies for hormone receptor-positive,...
GSK Inks $500M Upfront Deal with Hengrui for Respiratory Pipeline
GSK entered into a licensing agreement with Jiangsu Hengrui Pharmaceuticals for rights to a Phase I inhibitor targeting COPD along with 11 additional clinical programs in immunology and oncology....
Adaptimmune Sells Cell Therapy Assets Amid Financial Struggles
Adaptimmune announced the sale of its approved sarcoma therapy Tecelra and two late-stage clinical assets to US WorldMeds for $55 million upfront, with potential additional milestone payments. The...
AI Agents Advance Gene Set Analysis with Higher Accuracy
Researchers at the NIH developed GeneAgent, an AI-driven large language model system that autonomously verifies gene-set functional analysis predictions against expert-curated biological...
OpenAI CEO Highlights AI’s Growing Diagnostic Accuracy Over Physicians
OpenAI CEO Sam Altman stated that AI diagnostic tools have achieved accuracy levels superior to many human doctors. Altman pointed to AI’s potential to improve decision-making in drug development...
FDA Clears Sarepta's Duchenne Therapy to Resume Shipments for Ambulatory Patients
The FDA has reversed a previous recommendation and now allows Sarepta Therapeutics to resume shipments of its gene therapy Elevidys to ambulatory patients with Duchenne muscular dystrophy. This...
Celcuity Breast Cancer Therapy Hits Phase III Endpoints, Shares Surge
Celcuity reported positive results from its Phase III Viktoria-1 trial evaluating gedatolisib in hormone receptor-positive, HER2-negative breast cancer patients. The trial demonstrated significant...
GSK and Hengrui Pharma Ink $12 Billion Deal for Respiratory and Immunology Pipeline
GlaxoSmithKline (GSK) has entered a major licensing agreement with Jiangsu Hengrui Pharmaceuticals worth $500 million upfront and potential milestones totaling $12 billion. The deal grants GSK...
Adaptimmune Sells Cell Therapy Assets Amid Financial Strain
Adaptimmune announced the sale of its commercial cell therapy Tecelra and two late-stage assets to US WorldMeds for $55 million upfront, with potential additional payments of $30 million. The move...
AI-Powered Virtual Labs and Agents Revolutionize Biotech Research
Researchers at Stanford University and the NIH have developed advanced AI systems to accelerate biological research. Stanford’s virtual lab simulates interdisciplinary scientific collaboration...
Bristol Myers Squibb Spins Off $300M Immunology Venture with Multiple Assets
Bristol Myers Squibb has created a new spinout company focused on autoimmune diseases, transferring five assets including three clinical-stage drugs. The new entity is backed by $300 million from...
New Diagnostic and Therapeutic Tools Show Promise in Neurology and Oncology
Recent studies reveal breakthroughs in disease management: a novel plasma synuclein test enhances Parkinson’s diagnosis with improved sensitivity; a precise treatment timing strategy may boost...
Mass Administration of Ivermectin Reduces Malaria Transmission in Kenya
A large, cluster-randomized trial in Kenya demonstrates that mass drug administration of ivermectin to children reduces malaria infection incidence by 26%. As malaria control faces challenges from...